RAPTライブシグナル | Getagraph.comで利益を最大化

売る 158956 min ago

@ $24.99

発行日: 14 2月 2024 @ 05:43

リターン: -83.95%

前回のシグナル: 2月 13 - 23:30

前回のシグナル: 買う

リターン: 0.73 %

Live Chart Being Loaded With Signals

Commentary (1 6月 2024 @ 05:00):

Stats
本日の出来高	906 472
平均出来高	946 625
時価総額	139.96M
EPS	$0 ( 2024-05-22 )
次の収益日	( $-0.740 ) 2024-08-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.300
ATR14	$0.00700 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-22	Robbins Wendye	Buy	36 490	Stock Option (right to buy)
2024-05-23	Rieflin William Jl	Buy	36 490	Stock Option (right to buy)
2024-05-22	Lyons-williams Lori	Buy	36 490	Stock Option (right to buy)
2024-05-22	Kozick Linda	Buy	36 490	Stock Option (right to buy)
2024-05-22	Gray Mary Ann	Buy	36 490	Stock Option (right to buy)

INSIDER POWER
95.05
Last 100 transactions
Buy: 1 453 799 \| Sell: 63 895

ボリューム相関

長: -0.48 (neutral)

短: 0.53 (weak)

Signal:(32.787) Neutral

Rapt Therapeutics Inc 相関

10 最も正の相関
CYAN	0.945
LTRX	0.943
QDEL	0.94
WISA	0.938
IMKTA	0.938
SSRM	0.932
HFFG	0.931
VLCN	0.93
KRKR	0.93
AMCX	0.93

10 最も負の相関
MACK	-0.978
MEDP	-0.953
ADSE	-0.95
CRTO	-0.932
IBKR	-0.928
TXRH	-0.927
FREE	-0.927
SHLD	-0.921
TRVI	-0.917
VSEC	-0.917

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Rapt Therapeutics Inc 相関 - 通貨/商品

0.62
( weak )

0.68
( moderate )

0.00
( neutral )

0.40
( neutral )

-0.49
( neutral )

Rapt Therapeutics Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-3.55M (0.00 %)
EPS:	$-3.05

FY	2023
収益:	$0
総利益:	$-3.55M (0.00 %)
EPS:	$-3.05

FY	2022
収益:	$1.53M
総利益:	$-1.28M (-83.82 %)
EPS:	$-2.52

FY	2021
収益:	$3.81M
総利益:	$0.00 (0.00 %)
EPS:	$-2.53

Financial Reports:

No articles found.

Rapt Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Rapt Therapeutics Inc

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.